Key result
B4GALT1-CDG is linked to ~26% lower CETP activity and reduced LDL-c vs. controls.
Why the study?
To further investigate the role of protein glycosylation in regulating lipid metabolism by evaluating the effects of defective glycosylation on plasma lipids in patients with B4GALT1-CDG.
Does defective protein galactosylation in patients with B4GALT1-CDG reduce CETP activity and alter human lipoprotein homeostasis compared to healthy controls?
Case-Control (n=14)
Yes
Does defective protein galactosylation in patients with B4GALT1-CDG reduce CETP activity and alter human lipoprotein homeostasis compared to healthy controls?
This study highlights the mechanistic importance of protein glycosylation for CETP activity and lipid regulation, showing that B4GALT1 deficiency naturally lowers atherogenic lipoproteins.
B4GALT1-CDG may lower LDL-c via reduced CETP activity; hypothesis-generating for glycosylation's role in common dyslipidemias.
The importance of protein glycosylation in regulating lipid metabolism is becoming increasingly apparent. We set out to further investigate this by studying the effects of defective glycosylation on plasma lipids in patients with B4GALT1-CDG, caused by a mutation in B4GALT1 with defective N-linked glycosylation. We studied plasma lipids, cholesteryl ester transfer protein (CETP) glyco-isoforms with isoelectric focusing followed by a western blot and CETP activity in three known B4GALT1-CDG patients and compared them with 11 age- and gender-matched, healthy controls. B4GALT1-CDG patients have significantly lowered non-high density lipoprotein cholesterol (HDL-c) and total cholesterol to HDL-c ratio compared with controls and larger HDL particles. Plasma CETP was hypoglycosylated and less active in B4GALT1-CDG patients compared to matched controls. Our study provides insight into the role of protein glycosylation in human lipoprotein homeostasis. The hypogalactosylated, hypo-active CETP found in patients with B4GALT1-CDG indicates a role of protein galactosylation in regulating plasma HDL and LDL. Patients with B4GALT1-CDG have large HDL particles probably due to hypogalactosylated, hypo-active CETP.
No takes yet. Share an insight, caveat, or question.
Boogert et al. (2019) conducted a case-control in B4GALT1-CDG (n=14). B4GALT1-CDG mutation (defective N-linked glycosylation) vs. Age- and gender-matched healthy controls was evaluated on Endogenous CETP activity (26% reduction, p=0.019). B4GALT1-CDG patients demonstrated a 26% reduction in plasma CETP activity (20% vs 27%, p=0.019) and significantly lower LDL-c compared to matched healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: